Table 1.
Clinical characteristic of MPAL at diagnosis
| Total | B/Myeloid | T/Myeloid | Ph+MPAL | MLL MPAL | MPAL NOS | |
|---|---|---|---|---|---|---|
| N | 36 | 13 | 11 | 5 | 5 | 2 |
| Men | 21 (58%) | 7 (54%) | 6 (55%) | 4 (80%) | 2 (40%) | 2 (100%) |
| Median age, years (range) | 27 (1–69) | 17 (1–65) | 37 (14–69) | 45 (18–60) | 15 (2–29) | 15 (3–27) |
| Age <18 | 13 (36%) | 7 (54%) | 2 (18%) | 0 (0%) | 3 (60%) | 1 (50%) |
| Clinical features | ||||||
| Splenomegaly | 9 (25%) | 4 (33%) | 1 (9%) | 2 (50%) | 1 (20%) | 1 (50%) |
| Adenopathy | 11 (32%) | 2 (17%) | 6 (55%) | 1 (25%) | 0 (0%) | 2 (100%) |
| Sarcoma | 5 (15%) | 0 (0%) | 3 (27%) | 0 (0%) | 2 (40%) | 0 (0%) |
| CNS involvement | 7 (19%) | 4 (31%0 | 1 (9%) | 0 (0%0 | 1 (20%) | 1 (50%) |
| CBC, median (range) | ||||||
| WBC (x10^9/L) | 13.5 (0.5–200) | 9.9 (0.5–71) | 37.2 (8.1–143) | 60.2 (34.7–130.5) | 169.3 (1.9–200) | 13.5 |
| Hb (g/dL) | 10 (5.5–14.1) | 9.4 (5.5–13.1) | 10.7 (6.6–13.3) | 10.8 (10–14.1) | 7 (6.5–7.3) | 12.7 (12.7–12.7) |
| Plt (x10^9/L) | 114 (9–341) | 109.5 (28–341) | 104.5 (14–333) | 139 (123–327) | 11 (9–26) | 235 (235–235) |
| Cytogenetics | ||||||
| Normal | 4 (11%) | 2 (15%) | 2 (20%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Complex | 14 (40%) | 3 (23%) | 4 (36%) | 4 (80%) | 2 (40%) | 1 (50%) |
| -7/7q | 5 (14%) | 1 (8%) | 2 (18%) | 0 (0%) | 1 (20%) | 0 (0%) |
| t 14(q31-32) | 4 (11%) | 0 (0%) | 4 (36%) | 0 (0%) | 0 (0%) | 0 (0%) |
| +21 | 6 (17%) | 5 (38%) | 0 (0%) | 0 (0%) | 1 (20%) | 0 (0%) |
| Molecular | ||||||
| Rearranged TCR | 10/15 (67%) | 3 (75%) | 4 (67%) | 1 (33%) | 1 (100%) | 1 (100%) |
| Rearranged BCR | 3/8 (38%) | 1 (50%) | 0/2 | 2 (100%) | 0/1 | 0/0 |
| Induction type | ||||||
| AML-type# | 25 (69%) | 9 | 7 | 4 | 3 | 1 |
| ALL-type^ | 11 (31%) | 4 | 4 | 1 | 2 | 1 |